100% Objective Response Rate Across All Dose Levels
Complete Response Achieved Even at Lowest Dose
"Entering Phase to Determine Optimal Dose and Dosing Schedule"

RigaChemBio's ROR1-targeted antibody-drug conjugate (ADC) candidate LCB71 (CS5001) achieved a complete response rate (CR) of 100% across all dose levels in a first-line treatment combination clinical trial for diffuse large B-cell lymphoma (DLBCL).


On August 28, RigaChemBio announced that its partner company, CStone Pharmaceuticals, had released clinical data on the first-line DLBCL combination therapy with LCB71 in its half-year business report.


RigaChemBio logo image. RigaChemBio

RigaChemBio logo image. RigaChemBio

View original image

In the first-line DLBCL cohort evaluating combination therapy with the standard of care, R-CHOP, LCB71 demonstrated an objective response in all 31 evaluable patients across the 40–90μg/kg dose range, resulting in an objective response rate (ORR) of 100%. Each dose group also achieved a complete response rate (CR) of 100%.


Notably, complete response was confirmed even at the lowest dose of 40μg/kg. Based on this, the research team believes that it will be possible to explore a therapeutic window for LCB71 that maintains efficacy while ensuring safety and tolerability.


LCB71 is an ADC candidate jointly developed by RigaChemBio and ABL Bio, and subsequently out-licensed to CStone. It incorporates RigaChemBio’s tumor-selective cleavable linker technology and an in-house developed pyrrolobenzodiazepine (PBD) prodrug payload. Clinical development is currently underway in patients with first- and second-line DLBCL. Previous clinical studies have also confirmed anti-tumor activity.


According to CStone, the clinical trial will be temporarily suspended in order to comprehensively assess long-term efficacy and safety based on the accumulated clinical data, and to finalize the optimal dose and dosing schedule.


Since complete response was observed even at the lowest dose of 40μg/kg, future focus will be placed on identifying an appropriate dose and dosing interval that maintains proven efficacy while improving tolerability. Specific clinical development plans will be determined through discussions between the two companies.



A RigaChemBio representative commented, "A 100% complete response rate across all dose levels in first-line DLBCL is an encouraging result supporting the clinical potential of a ROR1 ADC. Since strong efficacy was demonstrated even at a low dose, we expect to establish a highly competitive profile in late-stage clinical trials by determining the optimal dose."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing